Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

MIRA Pharmaceuticals, Inc. - Common Stock (NQ:MIRA)

0.8900 -0.0600 (-6.32%)
Streaming Delayed Price Updated: 3:35 PM EDT, Apr 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about MIRA Pharmaceuticals, Inc. - Common Stock

MIRA Pharmaceuticals Enrolls First Subjects in Phase 1 Clinical Trial of Ketamir-2 for Neuropathic Pain
Via ACCESS Newswire
MIRA Pharmaceuticals Signs Binding Letter of Intent to Acquire SKNY Pharmaceuticals, Securing a $5 Million Capital Infusion to Advance Weight Loss and Smoking Cessation Drug Development
Via ACCESS Newswire
MIRA Pharmaceuticals Expands Ketamir-2 Development with Topical Treatment for Localized Neuropathic and Inflammatory Pain
Via ACCESS Newswire
MIRA Pharmaceuticals Announces Approval and Initiation of Phase 1 Clinical Trial for Ketamir-2 in Neuropathic Pain
Via ACCESS Newswire
MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile With No Adverse Findings, Paving the Way for IND Submission by Year-End
Via ACCESSWIRE
MIRA Reveals Innovative Phase I/IIa Protocol Design and Selection of Clinical Trial Site
Via ACCESSWIRE
MIRA Pharmaceuticals Achieves 100% Reversal of Neuropathic Pain With Oral Ketamir-2 in Breakthrough Study
Via ACCESSWIRE
MIRA Pharmaceuticals Announces Positive Discovery of Ketamir-2’s Selective NMDA Binding Mechanism of Action
Via ACCESSWIRE
MIRA Pharmaceuticals Submits IND for Ketamir-2 to FDA, Marking a Significant Milestone in the Company's Pipeline Development
Via ACCESSWIRE
MIRA Pharmaceuticals' Ketamir-2 Shows 60% Greater Efficacy Than FDA-Approved Gabapentin in Reversing Chemotherapy-Induced Neuropathic Pain
Via ACCESSWIRE
MIRA Pharmaceuticals Announces Ketamir-2 Outperforms Current FDA-Approved Neuropathic Pain Treatments, Gabapentin and Pregabalin, in Preclinical Study
Via ACCESSWIRE
MIRA Pharmaceuticals Announces New Preclinical Data for Ketamir-2 to Be Presented at the 18th Annual Pain Therapeutics Summit in Boston on October 28-29, 2024
Via ACCESSWIRE
MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing on Early Clinical Efficacy Demonstration for Neuropathic Pain in 2025
Via ACCESSWIRE
MIRA Pharmaceuticals Reveals Preclinical Success: Ketamir-2 Optimized for Brain Delivery, Avoiding Ketamine's Drug Resistance
Via ACCESSWIRE
Mira Pharmaceuticals Announces Promising Results for MIRA-55 in Multiple Preclinical Tests Compared to THC
Via ACCESSWIRE
MIRA Pharmaceuticals Designates Neuropathic Pain as Primary Indication for Ketamir-2 and Submits Pre-IND Meeting Request to FDA
Via ACCESSWIRE
MIRA Pharmaceuticals Showcases Significant Progress and Announces Final Phase of Regulatory Work as It Prepares for IND Submission by Year-End
Via ACCESSWIRE
MIRA Pharmaceuticals Unveils Ketamir-2's Principal Metabolite: Nor-Ketamir - a Longer-Acting, Brain Penetrating and Selective Compound Acting on the NMDA PCP Receptor
Via ACCESSWIRE
MIRA Pharmaceuticals, Inc. Discusses Potential of Revolutionary THC Analog Drug, MIRA1a, with The Stock Day Podcast
Via ACCESSWIRE
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.